Important Safety Information for Patients Taking Epysqli™ ▼ (eculizumab)

▼ 'This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.'

Epysqli can lower the ability of your immune system to fight

infections, especially meningococcal infection, **which requires immediate medical attention**.

If you experience any of the following symptoms, you should immediately call your doctor or seek emergency medical care, preferably in a major emergency medical care centre:

- headache with nausea or vomiting
- headache with a stiff neck or back
- fever
- rash
- confusion
- severe muscle aches combined with flu-like symptoms
- sensitivity to light

Get emergency medical care right away if you have any of these signs or symptoms and show this card.

Keep this card with you at all times during treatment and for 3 months after your last Epysqli dose. Your risk of meningococcal infection may continue for several weeks after your last dose of Epysqli.

INFORMATION FOR HEALTHCARE PROFESSIONALS

- **This patient has been prescribed Epsqli (eculizumab), which increases the patient's susceptibility to meningococcal infection (Neisseria meningitidis) or other general infections.**
- All patients must be vaccinated at least 2 weeks prior to receiving Epsqli. Patients who initiate Epsqli less than 2 weeks after receiving meningococcal vaccine must receive appropriate prophylactic antibiotics until 2 weeks after vaccination.
- Patients must receive vaccination and revaccination according to current national vaccination guidelines for vaccination use.
- Meningococcal infections may become rapidly life-threatening or fatal if not recognised and treated early.
- **Evaluate immediately if infection is suspected and treat with appropriate antibiotics if necessary.**
- Contact prescribing doctor (below) as soon as possible.

Adverse events should be reported. For more information about Epsqli, please refer to the full Summary of Product Characteristics or e-mail: bioepis.mi@medinformation.co.uk

Patient name _____

Hospital where treated _____

Physician name _____

Tel. number _____

Vaccination date(s) _____

Epsqli Treatment Initiation Date: _____

Meningococcal Vaccination information:

Vaccine Brand	Vaccine Serogroup	Dose Number	Date	Primary Series/ Booster Dose	Antibiotic prophylaxis received if Epsqli is initiated less than 2 weeks after receiving vaccine
					☐ Not Applicable ☐ Yes, start date:_____
					☐ Not Applicable ☐ Yes, start date:_____
					☐ Not Applicable ☐ Yes, start date:_____

Version: 1.0 (Dec 2025)